Ikarian Capital, LLC Bio Xcel Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$17.7 - $33.24 $2.07 Million - $3.89 Million	-116,986 Reduced 46.79%	133,014 $2.48 Million
Q4 2022 Feb 14, 2023	BUY	$10.25 - $22.43 $2.56 Million - $5.61 Million	250,000 New	250,000 $5.37 Million
Q2 2022 Aug 12, 2022	SELL	$9.03 - $21.55 $49,014 - $116,973	-5,428 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$15.0 - $22.83 $3,915 - $5,958	261 Added 5.05%	5,428 $113,000
Q4 2021 Feb 14, 2022	BUY	$20.12 - $35.09 $103,960 - $181,310	5,167 New	5,167 $104,000
Q2 2021 Aug 16, 2021	SELL	$29.06 - $38.83 $152,041 - $203,158	-5,232 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$39.04 - $64.6 $98,302 - $162,662	2,518 Added 92.78%	5,232 $226,000
Q3 2020 Nov 16, 2020	SELL	$37.44 - $64.63 $9.96 Million - $17.2 Million	-266,104 Reduced 98.99%	2,714 $117,000
Q2 2020 Aug 14, 2020	SELL	$17.62 - $58.71 $7.49 Million - $24.9 Million	-424,898 Reduced 61.25%	268,818 $14.3 Million
Q1 2020 May 15, 2020	BUY	$12.26 - $41.14 $6.56 Million - $22 Million	535,343 Added 338.03%	693,716 $15.5 Million
Q4 2019 Jan 31, 2020	BUY	$4.05 - $14.61 $641,410 - $2.31 Million	158,373 New	158,373 $2.31 Million

3.14M

22.2K

40.2K

Ticker BTAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,022,500
Market Cap $14.3M
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.